WallStreetZenWallStreetZen

NASDAQ: HCAT
Health Catalyst Inc Stock

$7.76+0.06 (+0.78%)
Updated Dec 8, 2023
HCAT Price
$7.76
Fair Value Price
$10.17
Market Cap
$446.59M
52 Week Low
$6.60
52 Week High
$15.87
P/E
-3.46x
P/B
1.17x
P/S
1.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$290.02M
Earnings
-$123.62M
Gross Margin
45.6%
Operating Margin
-45.12%
Profit Margin
-42.6%
Debt to Equity
0.86
Operating Cash Flow
-$29M
Beta
1.19
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HCAT Overview

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HCAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HCAT ($7.76) is undervalued by 23.66% relative to our estimate of its Fair Value price of $10.17 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HCAT ($7.76) is significantly undervalued by 23.66% relative to our estimate of its Fair Value price of $10.17 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HCAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HCAT due diligence checks available for Premium users.

Be the first to know about important HCAT news, forecast changes, insider trades & much more!

HCAT News

Valuation

HCAT fair value

Fair Value of HCAT stock based on Discounted Cash Flow (DCF)
Price
$7.76
Fair Value
$10.17
Undervalued by
23.66%
HCAT ($7.76) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HCAT ($7.76) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HCAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HCAT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.46x
Industry
23.64x
Market
31.32x

HCAT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.17x
Industry
3x
HCAT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HCAT's financial health

Profit margin

Revenue
$73.8M
Net Income
-$22.0M
Profit Margin
-29.9%
HCAT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HCAT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$712.9M
Liabilities
$330.5M
Debt to equity
0.86
HCAT's short-term assets ($408.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HCAT's short-term assets ($408.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HCAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HCAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$3.1M
Investing
-$24.9M
Financing
$1.0M
HCAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HCAT vs Health Information Service Stocks

TickerMarket Cap1d %P/EP/B
HCAT$446.59M+0.78%-3.46x1.17x
SLGC$458.89M-3.56%-3.54x0.92x
LIFW$406.03M-10.12%-0.42x1.42x
TALK$391.00M+2.18%-10.17x3.32x
AMWL$342.21M-2.46%-0.49x0.68x

Health Catalyst Stock FAQ

What is Health Catalyst's quote symbol?

(NASDAQ: HCAT) Health Catalyst trades on the NASDAQ under the ticker symbol HCAT. Health Catalyst stock quotes can also be displayed as NASDAQ: HCAT.

If you're new to stock investing, here's how to buy Health Catalyst stock.

What is the 52 week high and low for Health Catalyst (NASDAQ: HCAT)?

(NASDAQ: HCAT) Health Catalyst's 52-week high was $15.87, and its 52-week low was $6.60. It is currently -51.1% from its 52-week high and 17.58% from its 52-week low.

How much is Health Catalyst stock worth today?

(NASDAQ: HCAT) Health Catalyst currently has 57,550,324 outstanding shares. With Health Catalyst stock trading at $7.76 per share, the total value of Health Catalyst stock (market capitalization) is $446.59M.

Health Catalyst stock was originally listed at a price of $39.17 in Jul 25, 2019. If you had invested in Health Catalyst stock at $39.17, your return over the last 4 years would have been -80.19%, for an annualized return of -33.28% (not including any dividends or dividend reinvestments).

How much is Health Catalyst's stock price per share?

(NASDAQ: HCAT) Health Catalyst stock price per share is $7.76 today (as of Dec 8, 2023).

What is Health Catalyst's Market Cap?

(NASDAQ: HCAT) Health Catalyst's market cap is $446.59M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Health Catalyst's market cap is calculated by multiplying HCAT's current stock price of $7.76 by HCAT's total outstanding shares of 57,550,324.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.